The Pill That Could Disrupt the Weight Loss Industry: A Cautionary Tale of Convenience and Cost The pharmaceutical industry often faces a paradox: as treatments become more effective, they can also introduce new challenges that limit their reach.
This is evident in the recent trial results for orforglipron, a once daily weight loss pill developed by Eli Lilly. Forglipron's success in beating oral semaglutide in a major clinical trial is impressive.
It offers better weight loss and blood sugar improvements than injectable drugs like Ozempic and Wegovy, with the added convenience of no refrigeration required and no special timing with meals.